NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.

Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line TB treatments.

Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.

Molecule targeting cholesterol catabolism of mycobacteria.

Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.

Compounds targeting energy metabolism (electron chain transport).

Compound targeting lysine transfer RNA synthase (LysS), which is an essential gene as assessed by transposon mutagenesis.

Mycobacterial membrane protein Large 3 compounds with potent in vitro inhibitory and bactericidal activity against M tuberculosis.

Natural product analogs active against Mycobacterium tuberculosis.

Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase.

Lead optimization program on BC1 inhibitors.

Mycothione reductase target exploration.

Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.